ReviewInternational urology and nephrology2018
Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies.
Review in International urology and nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Synbiotics, prebiotics and probiotics for people with chronic kidney disease.The Cochrane database of systematic reviews · 2023Pooled it
- Synbiotics, prebiotics and probiotics for solid organ transplant recipients.The Cochrane database of systematic reviews · 2022Pooled it
- Probiotics in septic acute kidney injury, a double blind, randomized control trial.Renal failure · 2023Trial
- Association of the newly proposed dietary index for gut microbiota and chronic kidney disease.International urology and nephrology · 2026Article
- Clinical Pharmacokinetic-Pharmacodynamic Relationships of Pharmacological Strategies for Attenuating p-Cresyl Sulfate in Patients with Kidney Disease.Clinical pharmacokinetics · 2025Article
- Astaxanthin activates the Nrf2/HO-1 pathway to attenuate indoxyl sulfate-induced oxidative stress and DNA damage in renal tubular epithelial cells.Frontiers in pharmacology · 2025Article
- Causal relationship between gut microbiota and chronic renal failure: a two-sample Mendelian randomization study.Frontiers in microbiology · 2024Article
- The Diagnostic Potential of the Human Blood Microbiome: Are We Dreaming or Awake?International journal of molecular sciences · 2023Review
- A novel model of adenine-induced chronic kidney disease-associated gastrointestinal dysfunction in mice: The gut-kidney axis.Saudi journal of biological sciences · 2023Article
- A pilot study of alterations of the gut microbiome in canine chronic kidney disease.Frontiers in veterinary science · 2023Article
- Microbiota in health and diseases.Signal transduction and targeted therapy · 2022Review
- Preventive effects of theFrontiers in pharmacology · 2022Article
- Gut dysbiosis-influence on amygdala-based functional activity in patients with end stage renal disease: a preliminary study.Brain imaging and behavior · 2020Article
- Abnormalities in gut microbiota and serum metabolites in hemodialysis patients with mild cognitive decline: a single-center observational study.Psychopharmacology · 2020Observational
- HInflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020Article
- Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis.Pflugers Archiv : European journal of physiology · 2020Review
- Focus on the Gut-Kidney Axis in Health and Disease.Frontiers in medicine · 2020Review
- Vaginal Microbiota and HPV Infection: Novel Mechanistic Insights and Therapeutic Strategies.Infection and drug resistance · 2020Review
- Gut Microbiota Shifts in Pup Athymic BALB/c Mice: An Updated Identification in Nude Mice.Animals : an open access journal from MDPI · 2019Article
- The gut microbiota-inflammation-brain axis in end-stage renal disease: perspectives from default mode network.Theranostics · 2019Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The complicated communities of microbiota colonizing the human gastrointestinal tract exert a strong function in health maintenance and disease prevention. Indeed, accumulating evidence has indicated that the intestinal microbiota plays a key role in the pathogenesis and development of chronic kidney disease (CKD). Modulation of the gut microbiome composition in CKD may contribute to the accumulation of gut-derived uremic toxins, high circulating level of lipopolysaccharides and immune deregulation, all of which play a critical role in the pathogenesis of CKD and CKD-associated complications. In this review, we discuss the recent findings on the potential impact of gut microbiota in CKD and the underlying mechanisms by which microbiota can influence kidney diseases and vice versa. Additionally, the potential efficacy of pre-, pro- and synbiotics in the restoration of healthy gut microbia is described in detail to provide future directions for research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.